AMSBIO announce a new HER2 control cell line array that was developed and is proven as an effective slide quality control for HER2 expression in breast cancer tissue samples.
This new FFPE cell pellet microarray delivers a full dynamic range of HER2, ER and PR expression, validated by the Ventana system, to give immunohistochemical data in strong concordance with the routinely processed tissue sample.sections.
News
In our recent post, we have produced a clear summary infographic of all the key Covid-19 vaccines in full or early use, globally. We've included peer-review references where available, including efficacies, to help you to get up to speed quickly.
https://onyva-agency.com/2021/02/26/global-covid-19-vaccine-summary-and-...
New data reveals Knowledge Intensive (KI) firms in Cambridge continue to outperform national figures
Cambridge, UK. 3 March 2021: Medium term data on the growth of the Cambridge economy, right up to the start of the 2020 Covid lockdown, shows persistently higher annual growth rates than the national economy, particularly amongst knowledge-intensive (KI) firms. This confirms Cambridge’s status as one of the largest concentrations of KI employment in Europe. However, there are also indications that start-ups and non-KI firms are finding conditions in the city less attractive.
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs a
Cambridge, UK, 02 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
SOMERSET, N.J. and GOSSELIES, BELGIUM – February 23, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.
PLG is very excited to announce the re-start of our monthly newsletter, to keep everyone up to date with our activities and news.
Please see link:
https://productlifegroup.com/blog/february-newsletter/